TxCell Stock

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time Euronext Paris 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 12/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+2.35%+2.74%+38.10%+74.02% 56.54B
-0.21%-7.38%+27.52%+63.59% 53.6B
-2.44%+1.40%-15.61%-13.72% 22.91B
-2.85%-7.78%-9.28%+352.92% 21.37B
+2.49%-0.92%+23.57%-11.65% 20.27B
+0.79%-1.06%+33.99%-30.63% 17.56B
+0.58%-5.88%+19.40%+572.88% 14.75B
+3.41%-6.61%+162.81%+287.77% 13.53B
-5.25%-4.23%+42.32%+160.72% 13.33B
Average -0.11%-3.79%+35.87%+161.77% 25.98B
Weighted average by Cap. +0.23%-2.96%+30.79%+122.01%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
  1. Stock Market
  2. Stocks
  3. TXCL Stock